𩺠å
§ç§å°ç§èåç
ð äžé éé»
- 22E: AF rhythm control trial (EAST-AFNET)ãearly ablation strategyãwearable devices (Apple Watch)
- WPW + AF: avoid AVN block
- Brugada genetic screening
- Taiwan: catheter ablation å¥ä¿
ð é²éæ²»ç
AF
- Early rhythm control (EAST-AFNET) within 12 months
- Ablation > antiarrhythmic for selected
- Anticoagulation: DOAC > warfarin
- LAA closure for high-risk AC contraindication
SVT
- RFA cure rate > 95%
- AVNRT, AVRT WPW
- Long-term recurrence low
VT
- ICD for primary / secondary prevention
- Catheter ablation for monomorphic VT
- Genetic counseling for channelopathy
ð Pearls (8)
- Wearable detection: Apple Watch + Kardia æ¹è® AF detection
- EAST-AFNET 4 trial: early rhythm control benefit
- Catheter ablation > antiarrhythmic for AF in many
- DOAC ⥠warfarin for non-valvular AF
- WPW + AF procainamide (avoid AVN block)
- Brugada fever çŒç
- Long QT KCNQ1/KCNH2/SCN5A mutations
- Inappropriate sinus tachycardia: ivabradine
ð å°ç£ Context
- å¥ä¿ catheter ablation
- DOAC å¥ä¿ (apixaban, rivaroxaban, dabigatran, edoxaban)
- Brugada in Asia é« prevalence
- AF burden äžå with aging
ð å
§å°éé»
- 5 殺æ
- CHA2DS2-VASc + HAS-BLED
- WPW + AF
- Long QT / Brugada / CPVT
- AF rhythm control 22E
- ICD indications
è·šç« ç¯
- Ch 23 Syncope
- Ch 252-258 Arrhythmia
â ïž AI èçš¿ã